User login
Key clinical point: Methotrexate dosage may be tapered from targeted therapy in patients with controlled rheumatoid arthritis (RA) but with a low risk for not being able to sustain remission for up to 18 months.
Major finding: The ability to sustain remission for up to 18 months was 10% lower in patients with RA who tapered vs did not taper methotrexate from targeted therapy (risk ratio 0.90; 95% CI 0.84-0.97).
Study details: This was a systematic review and meta-analysis of 10 studies including 2000 patients with early or established RA who received any targeted therapy in combination with methotrexate and eventually tapered their methotrexate dosage.
Disclosures: This study was supported by the Hospital for Special Surgery, New York. Some authors reported receiving grants, honoraria or consulting fees, or owning stocks in various sources.
Source: Meng CF et al. Can patients with controlled rheumatoid arthritis taper methotrexate from targeted therapy and sustain remission? A systematic review and meta-analysis. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220152
Key clinical point: Methotrexate dosage may be tapered from targeted therapy in patients with controlled rheumatoid arthritis (RA) but with a low risk for not being able to sustain remission for up to 18 months.
Major finding: The ability to sustain remission for up to 18 months was 10% lower in patients with RA who tapered vs did not taper methotrexate from targeted therapy (risk ratio 0.90; 95% CI 0.84-0.97).
Study details: This was a systematic review and meta-analysis of 10 studies including 2000 patients with early or established RA who received any targeted therapy in combination with methotrexate and eventually tapered their methotrexate dosage.
Disclosures: This study was supported by the Hospital for Special Surgery, New York. Some authors reported receiving grants, honoraria or consulting fees, or owning stocks in various sources.
Source: Meng CF et al. Can patients with controlled rheumatoid arthritis taper methotrexate from targeted therapy and sustain remission? A systematic review and meta-analysis. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220152
Key clinical point: Methotrexate dosage may be tapered from targeted therapy in patients with controlled rheumatoid arthritis (RA) but with a low risk for not being able to sustain remission for up to 18 months.
Major finding: The ability to sustain remission for up to 18 months was 10% lower in patients with RA who tapered vs did not taper methotrexate from targeted therapy (risk ratio 0.90; 95% CI 0.84-0.97).
Study details: This was a systematic review and meta-analysis of 10 studies including 2000 patients with early or established RA who received any targeted therapy in combination with methotrexate and eventually tapered their methotrexate dosage.
Disclosures: This study was supported by the Hospital for Special Surgery, New York. Some authors reported receiving grants, honoraria or consulting fees, or owning stocks in various sources.
Source: Meng CF et al. Can patients with controlled rheumatoid arthritis taper methotrexate from targeted therapy and sustain remission? A systematic review and meta-analysis. J Rheumatol. 2022 (Aug 15). Doi: 10.3899/jrheum.220152